← Human Trials & Peer-Reviewed Studies
A randomized, double-blind, placebo-controlled trial of the effect of monthly vitamin D supplementation in mild psoriasis.
Plain-language guide to PMID 28849682 (2018): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, psoriasis and psoriatic arthritis.
Key Facts
- PMID
- 28849682
- Journal
- The Journal of dermatological treatment
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Jarrett P et al. (4 authors)
- DOI
- 10.1080/09546634.2017.1373735
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of psoriasis and psoriatic arthritis in this randomized controlled trial publication.
To investigate the clinical effect of vitamin D3 supplementation on psoriasis from a community-dwelling population.
Who Took Part
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.
The primary outcome was the Psoriasis Area and Severity Index (PASI) and secondary outcomes were Physicians Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Psoriasis Disability Index (PDI).
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
What Was Measured
Topics PubMed links to this paper include Cholecalciferol, Dietary Supplements, Interleukin-17, Placebo Effect and Psoriasis.
The authors tagged it with the keywords Vitamin D, double-blind, mild, placebo-controlled and randomized.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with psoriasis and psoriatic arthritis.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (The Journal of dermatological treatment), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Psoriasis and psoriatic arthritis research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.